Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysis.
about
Inflammatory bowel disease surgery in the biologic eraHow I treat my inflammatory bowel disease-patients with thiopurines?Does long-term efficacy differ between infliximab and adalimumab after 1 year of continuous administration?: A STROBE-compliant retrospective cohort study.Clinical efficacy of adalimumab in Crohn's disease: a real practice observational study in Japan.Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease.The Efficacy of Infliximab Monotherapy versus Infliximab-Azathioprine Sequential Treatment in Crohn's Disease: Experience from a Tertiary Medical Center in ChinaClinical impact of immunomonitoring in the treatment of inflammatory bowel disease.Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management.Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn's disease.Medical versus surgical management of penetrating Crohn's disease: the current situation and future perspectives.More Dose-dependent Side Effects with Mercaptopurine over Azathioprine in IBD Treatment Due to Relatively Higher Dosing.Immunomodulators for the treatment of Crohn's disease in adults: optimal use and prospects for future drug treatments.Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis.Current evidence supporting mucosal healing and deep remission as important treatment goals for inflammatory bowel disease.Factors Associated with Discontinuation of Anti-TNF Inhibitors Among Persons with IBD: A Population-Based Analysis.Thiopurines and Methotrexate Use in IBD Patients in a Biologic Era.Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease.Preoperative Nutritional Conditioning of Crohn's Patients-Systematic Review of Current Evidence and Practice.Preventing disability in inflammatory bowel disease.Development of Clinical Prediction Models for Surgery and Complications in Crohn's Disease.Optimization of biologic therapy in Crohn's disease.Inflammatory Bowel Disease: Pathophysiology and Current Therapeutic Approaches.The body composition profile is associated with response to anti-TNF therapy in Crohn's disease and may offer an alternative dosing paradigm.Early Biologic Treatment in Pediatric Crohn's Disease: Catching the Therapeutic Window of Opportunity in Early Disease by Treat-to-Target.Changing treatment paradigms for the management of inflammatory bowel disease.Validation of Neutrophil CD64 Blood Biomarkers to Detect Mucosal Inflammation in Pediatric Crohn's Disease.A role for thiopurine metabolites in the synergism between thiopurines and infliximab in inflammatory bowel disease.Therapeutic Drug Monitoring to Guide Infliximab Dose Adjustment is Associated with Better Endoscopic Outcomes than Clinical Decision Making Alone in Active Inflammatory Bowel Disease.Thiopurine Metabolism in the Era of Combotherapy.Combination Therapy for Inflammatory Bowel Disease.Improvement of psychological status after infliximab treatment in patients with newly diagnosed Crohn's disease.Fecal Microbiota Signatures Are Associated with Response to Ustekinumab Therapy among Crohn's Disease Patients.
P2860
Q26745627-DC6401F4-F7E9-45D2-9B84-3F39FC3F0D14Q28076561-62DAF5C5-BF57-4227-81BA-FF2C3D9938B8Q33606172-18F944E4-4128-4AE3-B1B3-8841602FCFC7Q36089928-F7BCFCDB-75A8-49F7-A178-E2110B8041DAQ36175167-2E02D8DF-41FA-4897-926D-55552E0A9885Q37427620-27E4B0EA-6DE9-4B68-AA9A-343B6F693EDEQ37624487-FE7D937A-A63A-4581-8F25-88A125A04181Q38619950-6CA1A5CF-A6A1-4090-A32E-B0EAB8C4AD27Q38647797-991A0F7A-DEDE-441B-A89A-9267876B177DQ38668874-D6389147-2B96-4FC9-A2F9-D219833995D7Q38712266-220F1D77-C86B-42EF-B667-A46D8A61D22CQ38743666-CF5E447A-3026-4284-82AC-3C2F814796A2Q38752119-652A27F2-D692-4B14-9875-FC981DDB55BDQ38797791-02639907-38EC-46A3-85CB-F6E467094E75Q38950429-87B1B8B4-DEE6-4D12-9859-5D3409B19B12Q39119181-24F8982A-552D-497F-B283-C927B678AAAEQ39353122-8315331D-E43B-4E57-ADDB-1A38589A4A3BQ39354624-1717AFDE-1682-4492-9C9B-E9316AFF97B8Q45338711-3879A326-9D5C-4CD7-8B24-0DC4DB49F32BQ46027208-5C5C59AE-E478-4DC5-8449-25875211AF65Q47389870-EF265B6C-608D-4F4D-8B55-61B2D526AC69Q47961270-9F0D3DFF-800A-434B-8103-58BFA0EC56A6Q48021336-72169574-DC45-4AE6-A9D7-F47CF5A0834AQ48518781-963C6789-4792-4D1F-9BE1-14591AD7F2F1Q48537463-26F3C59A-8E87-4A8A-AB32-BD44A2913E17Q49616319-1E289C20-4F9F-4DAC-A64E-759B9AC0C32FQ49960165-D3E9D535-4174-4A57-BB27-01289F868179Q50652815-E1FD6D4C-B5E4-4B72-A053-39BCC92546FCQ50691937-58378DA9-30F7-43C7-8F38-51839BDB00B8Q54157729-13FFA83B-0360-464B-ACEC-625763037419Q54919523-D7CDE747-FECD-4694-8D3A-F8929F6642B1Q55026569-888B5B31-C806-45AC-A481-F0542579A521
P2860
Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysis.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Randomised clinical trial: dee ...... e - a SONIC post hoc analysis.
@en
type
label
Randomised clinical trial: dee ...... e - a SONIC post hoc analysis.
@en
prefLabel
Randomised clinical trial: dee ...... e - a SONIC post hoc analysis.
@en
P2093
P2860
P356
P1476
Randomised clinical trial: dee ...... e - a SONIC post hoc analysis.
@en
P2093
A Kornbluth
A Oortwijn
F J Cornillie
G J Mantzaris
G S Bevelander
J-F Colombel
P Rutgeerts
W Reinisch
P2860
P304
P356
10.1111/APT.13139
P407
P577
2015-03-01T00:00:00Z